Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04901169
PHASE2/PHASE3

Angiotensin II in Liver Transplantation

Sponsor: University of California, San Francisco

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the efficacy and safety of Angiotensin II as a second-line vasopressor (drug that raises the blood pressure) during liver transplantation.

Official title: Angiotensin II in Liver Transplantation (AngLT-1): A Pilot Randomized Controlled Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2022-06-28

Completion Date

2027-03-18

Last Updated

2026-03-20

Healthy Volunteers

No

Interventions

DRUG

Angiotensin II

Infusion of Angiotensin II initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.

DRUG

Saline

Infusion of 0.9% saline initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.

Locations (1)

University of California, San Francisco

San Francisco, California, United States